Generalization of Extinction Learning

Status Completed

Clinical Trial Summary

Fear, whether it occurs in humans suffering from an anxiety disorder or in experimental models with rodents, is reduced by exposing the frightened organism to the fearful stimulus in the absence of any negative consequences (i.e., extinction, or exposure therapy). However, fear often renews when the feared stimulus is encountered in a context different from the exposure context. In rats, the investigators found that interfering with the animal's ability to process contexts during extinction by administering an anticholinergic drug prevented fear renewal. This proposal will determine if the beneficial effect of this drug translates to exposure therapy in socially anxious humans. To this end, 100 individuals with Social Phobia who fear public speaking will undergo repeated sessions of exposure to public speaking, within a virtual reality context. Participants will be randomized to either drug placebo, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy. One month after completion of exposure therapy, context renewal will be tested by comparing physiological and subjective responses to public speaking in the same virtual context as used during exposure therapy versus a context different than the one used during exposure therapy. The goal is to identify the dose of Scopolamine associated with the greatest reduction in context renewal. In addition, a secondary analysis will attempt to identify those individuals who benefit most from Scopolamine-augmentation of exposure therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01900301
Study type	Interventional
Source	University of California, Los Angeles
Contact
Status	Completed
Phase	Phase 1
Start date	August 2013
Completion date	August 2017

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06274112` - Using TMS to Understand Neural Processes of Social Motivation	N/A
Completed	`NCT02554929` - Treatment of Social Anxiety Disorder and Selective Mutism	N/A
Completed	`NCT00684541` - Interpretation Modification Program for Social Phobia	N/A
Completed	`NCT00684320` - Attention Disengagement Training for Social Phobia	N/A
Completed	`NCT03247075` - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT	N/A
Completed	`NCT02811458` - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders	N/A
Withdrawn	`NCT04622930` - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)	N/A
Active, not recruiting	`NCT05018312` - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety	N/A
Active, not recruiting	`NCT05124639` - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders	N/A
Completed	`NCT05858294` - The Safety, Acceptability and Efficacy of Alena	N/A
Active, not recruiting	`NCT05600114` - Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder	Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Not yet recruiting	`NCT02924610` - Brief Intervention to Reduce Fear	Phase 4
Active, not recruiting	`NCT02592564` - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder	N/A
Recruiting	`NCT02305537` - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment	N/A
Terminated	`NCT03764644` - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders	N/A
Unknown status	`NCT01712321` - Study of Vilazodone to Treat Social Anxiety Disorder	N/A
Completed	`NCT01320800` - CBT for Social Anxiety Disorder Delivered by School Counselors	Phase 2
Completed	`NCT00872820` - Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder	N/A
Completed	`NCT00485888` - Flushing in Social Anxiety Disorder on Cipralex	Phase 2